Stryker Corporation

New York Stock Exchange
Back to all articles
Somewhat Bearish -45

Stryker (SYK) Stock Plummets to 52-Week Low Following Wells Fargo Downgrade

AI-generated analysis

📉 Stryker (SYK) shares plummeted 8.9% to a 52-week low of $275.10 following Wells Fargo's downgrade.

📊 Wells Fargo slashed its price objective from $418 to $348 and reduced 2026 revenue projections to $27,209M.

⚠️ The bank cited ongoing challenges in peripheral vascular product lines and hip and knee replacement divisions.

💰 Stryker posted Q2 adjusted earnings of $3.69 per share, surpassing analyst expectations of $3.49.

📈 Total revenue reached $6.59 billion, exceeding the consensus forecast of $6.58 billion.

🚀 Earnings per share expanded 18% versus the corresponding quarter last year to $3.69.

🎯 Management established full-year 2026 earnings guidance between $14.95 and $15.10 per share.

🏦 Wall Street maintains a 'Moderate Buy' consensus with a price target of $386.28.

💸 Company insiders offloaded more than 351,000 shares totaling approximately $118.2 million recently.

💵 Stryker announced a quarterly dividend of $0.88 per share for payment on October 30th.

🏛️ California State Teachers Retirement System owns 163.4 million shares valued at approximately $51.4 billion.

📉 Some analysts trimmed targets due to supply chain disruptions and a cybersecurity incident.

Bullish Signals
  • Stryker posted Q2 adjusted earnings of $3.69 per share, surpassing analyst expectations of $3.49 by $0.20.
  • Total revenue reached $6.59 billion, marginally exceeding the $6.58 billion consensus forecast.
  • Second-quarter revenue increased 9.4% compared to the year-ago period with earnings per share expanding 18%.
  • Wall Street maintains a 'Moderate Buy' consensus rating with one Strong Buy recommendation and seventeen Buy ratings.
  • The consensus price objective stands at $386.28, representing substantial upside from current trading levels of $276.16.
  • Piper Sandler retained its Overweight designation while reducing its target to $390, maintaining a positive outlook.
  • JPMorgan lowered its objective to $350 while preserving its Overweight view on the medical device maker.
  • Wolfe Research elevated its price target to $375 from $350 while maintaining an Outperform recommendation.
  • Stryker announced a quarterly dividend distribution of $0.88 per share with an annual yield of approximately 1.3%.
  • California State Teachers Retirement System significantly expanded its position, owning 163.4 million shares.
Risk Factors
  • Wells Fargo slashed its price objective from $418 down to $348 following a presentation at the 2026 Healthcare Conference.
  • The investment bank reduced 2026 revenue projections to $27,209M, falling short of management's guidance range.
  • Wells Fargo reduced its third-quarter organic growth forecast to 8.9% from 10.1% due to ongoing challenges.
  • Ongoing challenges in peripheral vascular product lines and hip and knee replacement divisions are expected through year-end.
  • Citizens trimmed its target to $400 from $440, highlighting supply chain disruptions and a cybersecurity incident.
  • Company insiders offloaded more than 351,000 shares totaling approximately $118.2 million in the past three months.
  • The stock now trades significantly beneath both its 50-day moving average of $327.52 and 200-day moving average of $328.30.
Full Analysis
Stryker Corporation (SYK) shares experienced a sharp decline of 8.9% on Wednesday, trading at $276.16 and hitting a 52-week low of $275.10. This significant drop followed a downgrade by Wells Fargo, which slashed its price objective from $418 to $348 despite maintaining an Overweight rating. The investment bank reduced its 2026 revenue projection to $27,209 million and lowered its third-quarter organic growth forecast to 8.9%, citing ongoing challenges in peripheral vascular product lines and hip and knee replacement divisions. Despite the recent analyst downgrade, Stryker reported strong Q2 2026 financial results on July 30th, posting adjusted earnings of $3.69 per share that surpassed analyst expectations. Total revenue reached $6.59 billion, exceeding the consensus forecast, with a 9.4% increase compared to the year-ago period and an 18% expansion in earnings per share. Management has provided full-year 2026 earnings guidance between $14.95 and $15.10 per share, positioning the adjusted estimate at the lower boundary of this range. Wall Street sentiment remains largely favorable with a consensus 'Moderate Buy' rating and a price target of $386.28, representing substantial upside from current levels. While some analysts like Citizens trimmed targets due to supply chain disruptions and cybersecurity incidents, others like Piper Sandler and JPMorgan retained their Overweight designations. Insider trading activity saw company insiders dispose of over 351,000 shares totaling approximately $118.2 million in the past three months. The medical device manufacturer also announced a quarterly dividend distribution of $0.88 per share scheduled for payment on October 30th to shareholders registered as of September 30th. The annual dividend totals $3.52, representing a yield of approximately 1.3%. Institutional investors like California State Teachers Retirement System have significantly expanded their positions, currently owning 163.4 million shares valued at approximately $51.4 billion.